<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451331</url>
  </required_header>
  <id_info>
    <org_study_id>HCRN GU16-287</org_study_id>
    <nct_id>NCT03451331</nct_id>
  </id_info>
  <brief_title>Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer</brief_title>
  <official_title>Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Galsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase 2 trial of gemcitabine + carboplatin + nivolumab or gemcitabine +&#xD;
      oxaliplatin + nivolumab for the treatment of cisplatin-ineligible patients with metastatic&#xD;
      urothelial cancer. Randomization will be stratified on the lymph node only (and/or&#xD;
      unresectable primary) metastatic status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to Arm A: gemcitabine plus carboplatin plus nivolumab versus Arm&#xD;
      B: gemcitabine plus oxaliplatin plus nivolumab. Randomization will be stratified on the&#xD;
      metastasis status (lymph node only vs. the rest). Patients on both treatment arms will&#xD;
      receive up to 6 cycles of combination therapy in the absence of prohibitive adverse effects&#xD;
      or disease progression. Patients with at least stable disease at the completion of 6 cycles&#xD;
      of treatment may continue &quot;maintenance&quot; single agent nivolumab for up to 24 cycles. Patients&#xD;
      who require discontinuation of chemotherapy (i.e., gemcitabine plus carboplatin or&#xD;
      gemcitabine plus oxaliplatin) prior to Cycle 6, but who have at least stable disease, may be&#xD;
      considered for ongoing treatment with single-agent nivolumab on the &quot;maintenance&quot; phase after&#xD;
      discussion with the sponsor-investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1.5 years</time_frame>
    <description>(RECIST 1.1) to treatment with gemcitabine + carboplatin + nivolumab and gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Safety</measure>
    <time_frame>1.5 years</time_frame>
    <description>Assess all adverse events according to the NCI Common Terminology Criteria for (NCI CTCAE) v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>1.5 years</time_frame>
    <description>Time from the first documentation of RECIST 1.1 response to the time of progression as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time from randomization to death or progression, depending on which occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Metastatic Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine plus carboplatin plus nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine plus oxaliplatin plus nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting ~ 2-4 weeks after completing combination chemotherapy plus nivolumab)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>OPDIVO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 4.5 (based on the Calvert formula)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Paraplatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject must meet all the following applicable inclusion criteria to participate in this&#xD;
        study:&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information prior to registration. NOTE: HIPAA authorization may be included in the&#xD;
             informed consent or obtained separately.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of = 2&#xD;
&#xD;
          -  Able to comply with the study protocol, in the investigator's judgment.&#xD;
&#xD;
          -  Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or&#xD;
             metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed TCC or UCC of the&#xD;
             urinary tract; including renal pelvis, ureters, urinary bladder, and urethra) Patients&#xD;
             with mixed histologies are required to have a dominant transitional cell pattern.&#xD;
             Locally advanced bladder cancer must be inoperable on the basis of involvement of&#xD;
             pelvic sidewall or adjacent viscera (clinical Stage T4b) or bulky nodal metastasis&#xD;
             (N2-N3).&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST v1.1&#xD;
&#xD;
          -  Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (metastatic&#xD;
             specimens preferable but if not available primary tumor specimens that are at least&#xD;
             muscle-invasive are acceptable) in paraffin blocks (blocks preferred) or at least 15&#xD;
             unstained slides. Subjects without adequate archival tumor tissue or for whom a biopsy&#xD;
             is not considered possible may be considered for enrollment on a case by case basis&#xD;
             after discussion with the sponsor-investigator.&#xD;
&#xD;
          -  No prior chemotherapy for inoperable locally advanced or mUC. For patients who&#xD;
             received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial&#xD;
             carcinoma, a treatment-free interval &gt; 12 months between the last treatment&#xD;
             administration and the date of recurrence is required in order to be considered&#xD;
             treatment naive in the metastatic setting.&#xD;
&#xD;
          -  Cisplatin-ineligible as defined by at least one of the following:&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 (Cockroft-Gault)&#xD;
&#xD;
               -  ECOG performance status of 2 or greater&#xD;
&#xD;
               -  CTCAE v4 Grade ≥ 2 audiometric hearing loss&#xD;
&#xD;
          -  Demonstrate adequate organ function. All screening labs to be obtained within 28 days&#xD;
             prior to registration:&#xD;
&#xD;
               -  Hematological:&#xD;
&#xD;
                    -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
                    -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
                    -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Renal:&#xD;
&#xD;
                  • Calculated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)&#xD;
&#xD;
               -  Hepatic:&#xD;
&#xD;
                    -  Bilirubin ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert&#xD;
                       Syndrome, who can have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST) ≤ 3 × ULN&#xD;
&#xD;
                    -  Alanine aminotransferase (ALT) ≤ 3 × ULN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must use appropriate method(s) of&#xD;
             contraception as stated for the timeline below. Male subjects are not required to use&#xD;
             contraception.&#xD;
&#xD;
        NOTE: Women of childbearing potential is defined as any female who has experienced menarche&#xD;
        and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy)&#xD;
        or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in&#xD;
        a woman over 45 in the absence of other biological or physiological causes. In addition,&#xD;
        women under the age of 62 must have a documented serum follicle stimulating hormone (FSH)&#xD;
        level less than 40 mIU/mL.&#xD;
&#xD;
        NOTE: Women of childbearing potential (WOCBP) receiving nivolumab will be instructed to&#xD;
        adhere to contraception for a period of 5 months after the last dose of investigational&#xD;
        product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the criteria below may not participate in the study:&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the site&#xD;
             investigator, may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or&#xD;
             any other antibody or drug specifically targeting T-cell co-stimulation or immune&#xD;
             checkpoint pathways.&#xD;
&#xD;
          -  Grade ≥ 2 neuropathy (NCI CTCAE version 4).&#xD;
&#xD;
          -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or&#xD;
             chronic infection.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class III or greater), myocardial infarction within 3 months prior to randomization,&#xD;
             unstable arrhythmias, or unstable angina.&#xD;
&#xD;
          -  Known left ventricular ejection fraction (LVEF) &lt; 40% Patients with known coronary&#xD;
             artery disease, congestive heart failure not meeting the above criteria, or LVEF&#xD;
             40%-50% must be on a stable medical regimen that is optimized in the opinion of the&#xD;
             treating physician, in consultation with a cardiologist if appropriate.&#xD;
&#xD;
          -  Solid organ or tissue transplant including stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Galsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai; Tisch Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theuer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosiercancer.org</url>
    <description>Hoosier Cancer Research Network Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Matthew Galsky</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>cisplatin-ineligible</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>carboplatin</keyword>
  <keyword>nivolumab</keyword>
  <keyword>oxaliplatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

